GT Biopharma issued two new patents covering TriKE platform technologies

CAR T-Cell Immunotherapy
luismmolina/iStock via Getty Images

  • GT Biopharma (NASDAQ:GTBP) announces that the United States Patent and Trademark Office (USPTO) has issued 2 new patents covering the company's TriKE platform technologies.
  • "The granting of these patents provide us the necessary protection to continue to expand our clinical development path forward," CEO Anthony Cataldo said.
  • Shares up more than 3% premarket.
  • The company had posted interim results from a Phase 1 trial for its recombinant fusion protein conjugate, GTB-3550 in the treatment of high-risk myelodysplastic syndromes (MDS) and refractory/relapsed acute myeloid leukemia (AML), in June.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.